Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. 1992

M Versiani, and A E Nardi, and F D Mundim, and A B Alves, and M R Liebowitz, and R Amrein

In a double-blind, parallel group trial, 78 subjects with social phobia received moclobemide (a new reversible inhibitor of monoamine oxidase A) phenelzine, or placebo. After eight weeks, both active drugs-phenelzine somewhat more than moclobemide--were clinically and statistically significantly more effective than placebo, as assessed by rating scales. There was some further improvement between weeks 8 and 16, particularly in the moclobemide group; at week 16, 82% of the moclobemide and 91% of the phenelzine-treated patients were almost asymptomatic. Moclobemide was, however, much better tolerated than phenelzine. Patients withdrawn from active drugs had relapsed by week 24, providing additional support for the efficacy of the active drugs.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008996 Monoamine Oxidase Inhibitors A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p414) MAO Inhibitor,MAO Inhibitors,Reversible Inhibitors of Monoamine Oxidase,Monoamine Oxidase Inhibitor,RIMA (Reversible Inhibitor of Monoamine Oxidase A),Reversible Inhibitor of Monoamine Oxidase,Inhibitor, MAO,Inhibitor, Monoamine Oxidase,Inhibitors, MAO,Inhibitors, Monoamine Oxidase
D010554 Personality Disorders A major deviation from normal patterns of behavior. Avoidant Personality Disorder,Impulse-Ridden Personality,Inadequate Personality,Avoidant Personality Disorders,Impulse Ridden Personality,Personality Disorder,Personality Disorder, Avoidant,Personality Disorders, Avoidant,Personality, Impulse-Ridden,Personality, Inadequate
D010555 Personality Inventory Check list, usually to be filled out by a person about himself, consisting of many statements about personal characteristics which the subject checks. Edwards Personal Preference Schedule,Myers-Briggs Type Indicator,Indicator, Myers-Briggs Type,Inventories, Personality,Inventory, Personality,Myers Briggs Type Indicator,Personality Inventories
D010624 Phenelzine One of the MONOAMINE OXIDASE INHIBITORS used to treat DEPRESSION; PHOBIC DISORDERS; and PANIC. Fenelzin,2-Phenethylhydrazine,Nardelzine,Nardil,Phenelzine Sulfate,Phenethylhydrazine,beta-Phenylethylhydrazine,2 Phenethylhydrazine,Sulfate, Phenelzine,beta Phenylethylhydrazine
D010698 Phobic Disorders Anxiety disorders in which the essential feature is persistent and irrational fear of a specific object, activity, or situation that the individual feels compelled to avoid. The individual recognizes the fear as excessive or unreasonable. Claustrophobia,Neuroses, Phobic,Phobia, School,Phobias,Phobic Neuroses,Scolionophobia,Disorder, Phobic,Phobia,Phobic Disorder,School Phobia
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D011569 Psychiatric Status Rating Scales Standardized procedures utilizing rating scales or interview schedules carried out by health personnel for evaluating the degree of mental illness. Factor Construct Rating Scales (FCRS),Katz Adjustment Scales,Lorr's Inpatient Multidimensional Psychiatric Rating Scale,Wittenborn Scales,Edinburgh Postnatal Depression Scale,Mini International Neuropsychiatric Interview
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses

Related Publications

M Versiani, and A E Nardi, and F D Mundim, and A B Alves, and M R Liebowitz, and R Amrein
July 1988, The Journal of clinical psychiatry,
M Versiani, and A E Nardi, and F D Mundim, and A B Alves, and M R Liebowitz, and R Amrein
January 1998, The British journal of psychiatry : the journal of mental science,
M Versiani, and A E Nardi, and F D Mundim, and A B Alves, and M R Liebowitz, and R Amrein
January 1997, European archives of psychiatry and clinical neuroscience,
M Versiani, and A E Nardi, and F D Mundim, and A B Alves, and M R Liebowitz, and R Amrein
August 1997, Journal of clinical psychopharmacology,
M Versiani, and A E Nardi, and F D Mundim, and A B Alves, and M R Liebowitz, and R Amrein
May 1998, The British journal of psychiatry : the journal of mental science,
M Versiani, and A E Nardi, and F D Mundim, and A B Alves, and M R Liebowitz, and R Amrein
April 1986, Journal of clinical psychopharmacology,
M Versiani, and A E Nardi, and F D Mundim, and A B Alves, and M R Liebowitz, and R Amrein
April 1992, Archives of general psychiatry,
M Versiani, and A E Nardi, and F D Mundim, and A B Alves, and M R Liebowitz, and R Amrein
January 1990, Psychopharmacology bulletin,
M Versiani, and A E Nardi, and F D Mundim, and A B Alves, and M R Liebowitz, and R Amrein
January 2003, Acta psychiatrica Scandinavica. Supplementum,
M Versiani, and A E Nardi, and F D Mundim, and A B Alves, and M R Liebowitz, and R Amrein
December 1993, The Journal of clinical psychiatry,
Copied contents to your clipboard!